^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.

Published date:
05/19/2021
Excerpt:
This is the first in human (FIH) phase I study of JPI-547 in patients (pts) with advanced solid tumors….At the time of data cut-off, three pts were ongoing as following response and cancer types:...SD (breast, gBRCAm, 9.3 mos).
DOI:
10.1200/JCO.2021.39.15_suppl.3113
Trial ID: